Abstract
The presence of numerous axon-inhibitory molecules limits the capacity of injured neurons in the adult mammalian central nervous system (CNS) to regenerate damaged axons. Among others, chondroitin sulphate proteoglycans (CSPGs) enriched in glycosaminoglycan (GAG) chains, acting intracellularly via Rho GTPase activation and cytoskeletal modification, prevent axon re-growth after injury. However, axon regeneration can be induced by modulating the extrinsic environment or the intrinsic neural response to axon extension. Among other strategies, the use of chondroitinase ABC (ChABC) to degrade GAGs and decrease CSPG-associated inhibition has been analyzed. Recent reports have extended the use of this enzyme, in combination with cell transplantation or pharmacological treatment. The steady advances made in these combinations offer promising perspectives for the development of new therapies to repair the injured nervous system.
Keywords: Chondroitin sulphate proteoglycans, axon regeneration, chondroitinase ABC, glial scar, Schwann cells, olfactory ensheathing glia, neural stem cells
Current Pharmaceutical Design
Title: Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Volume: 13 Issue: 24
Author(s): J.A. Del Rio and E. Soriano
Affiliation:
Keywords: Chondroitin sulphate proteoglycans, axon regeneration, chondroitinase ABC, glial scar, Schwann cells, olfactory ensheathing glia, neural stem cells
Abstract: The presence of numerous axon-inhibitory molecules limits the capacity of injured neurons in the adult mammalian central nervous system (CNS) to regenerate damaged axons. Among others, chondroitin sulphate proteoglycans (CSPGs) enriched in glycosaminoglycan (GAG) chains, acting intracellularly via Rho GTPase activation and cytoskeletal modification, prevent axon re-growth after injury. However, axon regeneration can be induced by modulating the extrinsic environment or the intrinsic neural response to axon extension. Among other strategies, the use of chondroitinase ABC (ChABC) to degrade GAGs and decrease CSPG-associated inhibition has been analyzed. Recent reports have extended the use of this enzyme, in combination with cell transplantation or pharmacological treatment. The steady advances made in these combinations offer promising perspectives for the development of new therapies to repair the injured nervous system.
Export Options
About this article
Cite this article as:
J.A. Del Rio and E. Soriano , Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC, Current Pharmaceutical Design 2007; 13 (24) . https://dx.doi.org/10.2174/138161207781368639
DOI https://dx.doi.org/10.2174/138161207781368639 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling
Current Medicinal Chemistry Protection of Blood Brain Barrier Integrity and Modulation of Inflammatory Mediators During Treatment of Pneumococcal Meningitis with Daptomycin or Ceftriaxone
Current Neurovascular Research The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Current Pharmaceutical Design Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization
Current Pharmacogenomics and Personalized Medicine Natural Compounds Therapeutic Features in Brain Disorders by Experimental, Bioinformatics and Cheminformatics Methods
Current Medicinal Chemistry Small Molecule Hydrazide Agents to Inhibit Growth and Proliferation of Mycobacterium Tuberculosis
Medicinal Chemistry Proteins in Microglial Activation - Inputs and Outputs by Subsets
Current Protein & Peptide Science New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Mouse Models of Multiple Sclerosis: Lost in Translation?
Current Pharmaceutical Design Carbapenem-Hydrolyzing Gram-Negative Bacteria: Current Options for Treatment and Review of Drugs in Development
Recent Patents on Anti-Infective Drug Discovery Health Care Providers’ Need for Child and Adolescent Mental Health (CAMH) Training in South Western Nigeria
Adolescent Psychiatry The Role of Microbial Agents in the Etiology of Schizophrenia: An Infectious Hypothesis for Psychosis?
Current Immunology Reviews (Discontinued) Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry Efficient Synthesis and Antibacterial Profile of Bis(2-hydroxynaphthalene- 1,4-dione)
Current Topics in Medicinal Chemistry Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy